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Abstract
Coagulase-negative staphylococci (CoNS) have been increasing in importance as a cause of native valve endocardi-
tis (NVE). Most cases of NVE caused by CoNS are attributable to Staphylococcus epidermidis. NVE caused by CoNS
acquired in a nosocomial setting may differ from cases acquired in the community in several ways. It may be asso-
ciated with hemodialysis, the presence of a long-term indwelling central catheter or pacemaker, or a recent inva-
sive procedure; nosocomial cases may have a higher rate of methicillin resistance among CoNS isolates, and so be
more likely to be treated with vancomycin. Unfortunately, NVE caused by methicillin-resistant CoNS has been asso-
ciated with significantly higher rates of persistent bacteremia and in-hospital mortality than methicillin-susceptible
isolates. The poor outcomes in these cases point to the need for alternative therapies with potent activity against
methicillin-resistant CoNS. In our medical center, a 76-year-old man presented with native-valve endocarditis and
positive blood cultures for methicillin-resistant Staphylococcus epidermidis (MRSE). During each of three 6-week
courses of treatment with vancomycin, blood cultures were negative, but they once again became positive for
MRSE when vancomycin was discontinued. The minimum inhibitory concentration of the MRSE isolates for vanco-
mycin remained stable at 2 μg/mL. Eventually, treatment with daptomycin was initiated (500 mg [7 mg/kg])
3 times/week for 6 weeks. Over the following year, no positive cultures for MRSE were detected.
Background
Coagulase-negative staphylococci (CoNS) have been
increasing in importance as a cause of native valve
endocarditis (NVE) [1-3]. According to recent data from
the International Collaboration of Endocarditis-Prospec-
tive Cohort Study (ICE-PCS), CoNS account for 7.8% of
all cases of NVE and cause death in one quarter of
these cases, even though a majority of patients undergo
surgical treatment [4]. In the ICE-PCS cohort, which
included 1635 patients from 61 centers in 28 countries
with definite NVE and no history of injection drug use,
the mortality rate for NVE caused by CoNS was com-
p a r a b l et ot h a tf o rN V Ec a u s e db yStaphylococcus aur-
eus and significantly higher than that for NVE caused by
viridans group streptococci [4].
Most cases of NVE caused by CoNS are attributable
to Staphylococcus epidermidis, including 80% of those in
the ICE-PCS cohort [4]. In this cohort, NVE caused by
CoNS acquired in a nosocomial setting differed from
cases acquired in a community-based setting in several
ways. Nosocomial cases were associated with several
predisposing factors, including hemodialysis, the pre-
sence of a long-term indwelling central catheter or pace-
maker, or a recent invasive procedure [4]. Notably,
nosocomial cases had a much higher rate of methicillin
resistance among CoNS isolates (58 versus 22%; P =
0.05), and consequently were more likely to be treated
with vancomycin (65 versus 25%; P < 0.01). In turn,
NVE caused by methicillin-resistant CoNS was asso-
ciated with significantly higher rates of persistent bacter-
emia (25 versus 9%; P = 0.01) and in-hospital mortality
(40 versus 16%; P = 0.03) than methicillin-susceptible
isolates. The poor outcomes in these cases point to the
need for alternative therapies with potent activity against
methicillin-resistant CoNS.
Daptomycin is a novel cyclic lipopeptide with activity
against most aerobic Gram-positive pathogens, including
strains resistant to methicillin, vancomycin, and other
antibiotics [5,6]. Daptomycin is highly active against
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(MRSE) [7-9]. Most clinical isolates of MRSE and other
methicillin-resistant CoNS are susceptible to daptomy-
cin at a minimum inhibitory concentration (MIC) of
0.5 μg/mL or less [10,11]. Daptomycin produces rapid,
concentration-dependent bactericidal activity, but its
mechanism differs from other antibiotics; it damages the
bacterial cell membrane but causes only minimal cell
lysis [12-14].
Daptomycin is approved by the US Food and Drug
Administration for the treatment of bloodstream infec-
tions, including right-sided infective endocarditis caused
by methicillin-resistant and -susceptible strains of S.
aureus as well as for complicated skin and skin structure
infections caused by susceptible Gram-positive patho-
gens [15]. In a randomized clinical trial, daptomycin was
as effective as a control regimen (low-dose gentamicin
plus either an antistaphylococcal penicillin or vancomy-
cin) in patients with bacteremia caused by S. aureus,
including the subset with right-sided endocarditis [16]
and those with methicillin-resistant strains [17]. A sub-
sequent systematic review of published case reports and
case series identified 19 patients with endocarditis who
had been treated with daptomycin, mostly after failure
of previous vancomycin therapy [18]. In one of these
cases, endocarditis with bacteremia was due to CoNS
and was treated successfully with daptomycin after van-
comycin failure [19]. In an experimental model of endo-
carditis caused by MRSE, daptomycin produced > 99.9%
kill rates by 8 hours after dosing and reduced bacterial
load to a greater degree than vancomycin at 1 to 3 days
[20].
The preclinical and clinical profiles of daptomycin
suggest that it should be useful in treating NVE caused
by CoNS, even after the failure of treatment with vanco-
mycin. This report describes a case of NVE caused by
MRSE that was treated successfully with daptomycin
after the patient failed multiple courses of vancomycin.
Case Presentation
A 76-year old man receiving dialysis for end-stage renal
disease was referred to our medical center because of
blood cultures repeatedly positive for CoNS (MRSE).
Over the previous 4 months, two infected hemodialysis
catheters had been removed, and for each episode, the
patient had been treated with a 2-week course of intra-
venous (IV) vancomycin, with trough drug levels main-
tained in the range of 15 to 20 μg/mL. After the second
episode, blood cultures became persistently positive for
C o N Sw i t h i n1w e e ko fd i s c o n t i n u i n gv a n c o m y c i n .A
transesophageal echocardiogram revealed moderate aor-
tic valve sclerosis and mild aortic regurgitation and
showed stringy masses attached to the aortic cusps sug-
gestive of a bacterial infection (left-sided endocarditis).
Low-grade fever was present. The patient reported hav-
ing some headaches and malaise but denied any chest
pain, shortness of breath, or other symptoms. Labora-
tory test results were: C-reactive protein, 1.9 mg/dL
(normal, < 0.5 mg/dL); erythrocyte sedimentation rate,
13 mm/hr; hemoglobin, 13.1 g/dL; hematocrit, 38.9%;
platelet count, 281,000/μL; and white blood cell count,
9,000/μL, with a differential of 43% neutrophils, 29%
lymphocytes, 16% monocytes, and 10% eosinophils.
Medical history
The patient’s medical history was significant for end-
stage renal disease caused by diabetic nephropathy, and
congestive heart failure with severely decreased left-ven-
tricular systolic function. The patient had undergone
hemodialysis 3 times per week for 4 years. The medical
history also showed coronary artery disease, gout, and
hyperlipidemia. In 1993, the patient had undergone cor-
onary artery bypass grafting followed by multiple angio-
plasties, but he was no longer a candidate for cardiac
surgery.
Initial treatment course
The patient was hospitalized for NVE on December 27,
2006. Two sets of blood cultures were positive for
MRSE (Figure 1). Vancomycin 500-1000 mg IV was
started after hemodialysis. Repeat blood cultures
obtained on January 16, 2007, showed S. epidermidis
(on one of two sets) that was susceptible (determined by
VITEK 2) to trimethoprim/sulfamethoxazole, linezolid,
vancomycin, and rifampin. The vancomycin MIC was
2 μg/mL. Rifampin 300 mg bid was added to vancomy-
cin on January 16. Four blood cultures obtained between
January 18 and February 8, while the patient was receiv-
ing vancomycin and rifampin, were negative. The first
course of antibiotics was discontinued on February 8.
Twelve days later, on February 20, two sets of blood cul-
t u r e sw e r ep o s i t i v ef o rS. epidermidis.T h eb a c t e r i u m
was sensitive to linezolid, rifampin, and vancomycin,
with the vancomycin MIC remaining at 2 μg/mL.
The patient was started on a second course of IV van-
comycin on February 22, while continuing with his dia-
lysis treatment. Trough drug levels were maintained in
the range of 15 to 20 μg/mL. The patient had minimal
symptoms, except for intermittent low-grade fever and
shortness of breath. Blood cultures obtained during the
second course of vancomycin were negative. Antibiotics
were discontinued on April 30, but 8 days later, blood
cultures were again positive for S. epidermidis.T h e
patient was started on a third course of IV vancomycin,
with a 500-mg dose given after each dialysis session.
Trough drug levels were still in the range of 15 to 20
μg/mL. Repeat blood cultures on May 10, June 25, and
June 27 were negative. The third course of vancomycin
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and July 14 were again positive for CoNS (MRSE). The
vancomycin MIC was 2 μg/mL, and the daptomycin
MIC was 0.75 μg/mL. On July 14, vancomycin was
restarted with rifampin 300 mg three times daily.
Further treatment course
The patient was admitted on July 27 with fever, chills,
and rigor. He was diagnosed with a central-line infection
caused by Enterobacter cloacae and received lock therapy
with IV ciprofloxacin 400 mg daily through his dialysis
catheter for 2 weeks. Vancomycin was discontinued.
Because the cultures on July 12 and 14 were positive for
MRSE, IV daptomycin 500 mg (7 mg/kg) after each dialy-
sis (3 times/week) was started and continued for 6 weeks,
until September 6. Blood cultures obtained on September
13 and 20 and October 2 were negative. Over the follow-
ing year, the patient did not have any recurrence of blood
cultures positive for S. epidermidis. The patient has
remained stable and continues to do well at 18 months
after discontinuing daptomycin.
Discussion
This patient is typical of those who are likely to develop
NVE caused by methicillin-resistant CoNS. Consistent
with the ICE-PCS cohort [4], the patient had several fac-
tors predictive of a poor outcome from NVE caused by
CoNS (persistent bacteremia, congestive heart failure,
and chronic illness). He also had predisposing factors
for methicillin-resistant CoNS (hemodialysis, long-term
indwelling catheter) that confer higher mortality. Dapto-
mycin successfully eradicated MRSE after the patient
had failed several courses of vancomycin. Although
blood cultures were negative during vancomycin treat-
ment, cultures positive for CoNS were seen within 1
week after vancomycin was withdrawn. In contrast,
blood cultures were negative during daptomycin treat-
ment and have remained negative for more than 1 year
after the 6-week course of daptomycin was completed.
The patient was treated with daptomycin at a dose of
500 mg (7 mg/kg) after each dialysis (3 times/week) for
6 weeks, which is generally consistent with the dosing
recommendation for daptomycin in patients with bacter-
emia and endocarditis caused by S. aureus [15]. For the
approved indication, daptomycin is recommended at a
dose of 6 mg/kg for 2 to 6 weeks based on the physi-
cian’s working diagnosis. Because daptomycin is elimi-
nated primarily by the kidneys, the once-daily dosing
schedule should be adjusted to once every 48 hours for
patients with significant renal impairment, including
those undergoing hemodialysis [15]. In this case, as dap-
tomycin was given with hemodialysis, the drug was
given 3 times/week.
Conclusions
Treatment with daptomycin 500 mg (7 mg/kg) 3 times/
week for 6 weeks enabled the patient, a 76-year old man
on hemodialysis who had presented with native valve
endocarditis, to clear blood cultures positive for MRSE,
after 3 courses of vancomycin did not. Treatment with
daptomycin offers patients like these an option even
after vancomycin failure.
Consent
Oral informed consent for publication of this case was
obtained from the patient. Written informed consent
was obtained from the patient’s next of kin (his wife) for
publication of this case report after the patient expired.
A copy of the written consent is available for review
from the Editor-in-Chief of this journal.
Figure 1 Timeline showing blood culture results for methicillin-resistant Staphylococcus epidermidis in relation to treatment.
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